Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
View through CrossRef
AbstractBackground and AimUlcerative colitis (UC) causes chronic inflammation in the digestive tract, leading to abdominal pain and diarrhea. Adalimumab, a monoclonal antibody, is used to treat moderate to severe cases. This review and meta‐analysis evaluated adalimumab's effectiveness for severe UC, considering patient age, disease duration, and gender.MethodsThis study was designed as a systematic review and a meta‐analysis. Articles were searched in PubMed, Scopus, and Web of Science databases based on the keywords of adalimumab and UC. The titles, the abstracts, and, if necessary, the full texts of the articles were read. Then for further review, the full texts of the related articles were carefully examined, and the final articles were selected. Seventy‐eight articles were searched based on the keywords, and after reading the articles, 50 articles were related to the topic of the dissertation. The 50 articles were evaluated critically based on a checklist prepared by a statistical consultant and four articles with a score above 70% were selected. In the four articles, the main indicators of the effectiveness of adalimumab, including mucosal healing, clinical remission, and clinical response, were evaluated.ResultsThe effectiveness of adalimumab on the mucosal healing index was 75.40%, the clinical remission index was 70.79%, and the clinical response index was 83.02%, based on different doses and treatment durations in the study. In the four meta‐analysis studies on adalimumab's effectiveness, 1613 UC patients were treated with varying doses over 8 and 52 weeks. Based on a meta‐analysis over 8 and 52 weeks for treating moderate to severe UC, adalimumab's effectiveness was 70%−83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.ConclusionAccording to the meta‐analysis, the effectiveness of adalimumab for treating moderate to severe UC over 8 and 52 weeks was 70%−83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.
Title: Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
Description:
AbstractBackground and AimUlcerative colitis (UC) causes chronic inflammation in the digestive tract, leading to abdominal pain and diarrhea.
Adalimumab, a monoclonal antibody, is used to treat moderate to severe cases.
This review and meta‐analysis evaluated adalimumab's effectiveness for severe UC, considering patient age, disease duration, and gender.
MethodsThis study was designed as a systematic review and a meta‐analysis.
Articles were searched in PubMed, Scopus, and Web of Science databases based on the keywords of adalimumab and UC.
The titles, the abstracts, and, if necessary, the full texts of the articles were read.
Then for further review, the full texts of the related articles were carefully examined, and the final articles were selected.
Seventy‐eight articles were searched based on the keywords, and after reading the articles, 50 articles were related to the topic of the dissertation.
The 50 articles were evaluated critically based on a checklist prepared by a statistical consultant and four articles with a score above 70% were selected.
In the four articles, the main indicators of the effectiveness of adalimumab, including mucosal healing, clinical remission, and clinical response, were evaluated.
ResultsThe effectiveness of adalimumab on the mucosal healing index was 75.
40%, the clinical remission index was 70.
79%, and the clinical response index was 83.
02%, based on different doses and treatment durations in the study.
In the four meta‐analysis studies on adalimumab's effectiveness, 1613 UC patients were treated with varying doses over 8 and 52 weeks.
Based on a meta‐analysis over 8 and 52 weeks for treating moderate to severe UC, adalimumab's effectiveness was 70%−83%.
The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.
ConclusionAccording to the meta‐analysis, the effectiveness of adalimumab for treating moderate to severe UC over 8 and 52 weeks was 70%−83%.
The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Ulcerative colitis is a multifactorial, chronic inflammatory disease of the bowel that can cause physical, social and emotional injury to the patient. While perhaps not always maki...
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Background: Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) characterized by intestinal inflammation confined to the superficial mucosal layer. Mesalazi...
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatri...
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Background/Objectives: Dose escalation has been commonly used to achieve and maintain response. We aimed to compare the outcomes of adalimumab or infliximab dose escalation in infl...
P0193 Oral administration of Sophora Flavescens-derived exosomes-like nanovesicles carrying CX5461 ameliorates DSS-induced colitis in mice
P0193 Oral administration of Sophora Flavescens-derived exosomes-like nanovesicles carrying CX5461 ameliorates DSS-induced colitis in mice
Abstract
Background
Ulcerative colitis (UC) belongs inflammatory disease with chronic and relapsing characterizations and increa...
Dual-pathway mechanisms of plant-derived polysaccharides in ulcerative colitis: integrative roles of microbiota modulation, immune regulation, and barrier restoration
Dual-pathway mechanisms of plant-derived polysaccharides in ulcerative colitis: integrative roles of microbiota modulation, immune regulation, and barrier restoration
Chronic inflammation of the colon has been described as an inflammatory condition of the colon that is characterized by recurring flare-ups of the disease (ulcerative colitis). Ulc...
Pharmacological correction of ulcerative colitis with dalargin
Pharmacological correction of ulcerative colitis with dalargin
Introduction: Ulcerative colitis is a chronic colonic disease with frequent relapses, affecting mainly people of active age. The effectiveness of existing treatment methods remains...